Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Dare Bioscience, Inc. | ceru-ex991_27.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 10, 2016
CERULEAN PHARMA INC.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
001-36395 |
20-4139823 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
35 Gatehouse Drive Waltham, MA |
|
02451 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (781) 996-4300
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On March 10, 2016, Cerulean Pharma Inc. (the “Company”) issued a press release announcing, among other things, the Company’s operational highlights for the fourth quarter and year ended December 31, 2015 and anticipated corporate and clinical milestones for 2016. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
The information provided under Item 2.02 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
|
|
(d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: |
||||
|
Exhibit No. |
|
Description |
|||
|
|
|
||||
|
99.1 |
|
Press release dated March 10, 2016. |
|||
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CERULEAN PHARMA INC. |
||||
|
|
|
|
|
|||||
|
Date: March 10, 2016 |
|
|
|
By: |
|
/s/ Christopher D.T. Guiffre |
||
|
|
|
|
|
|
|
|
|
Christopher D.T. Guiffre President and Chief Executive Officer |
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press release dated March 10, 2016. |